KR102828472B1 - 키나아제 억제제의 결정질 형태 및 염 형태 - Google Patents
키나아제 억제제의 결정질 형태 및 염 형태 Download PDFInfo
- Publication number
- KR102828472B1 KR102828472B1 KR1020217021734A KR20217021734A KR102828472B1 KR 102828472 B1 KR102828472 B1 KR 102828472B1 KR 1020217021734 A KR1020217021734 A KR 1020217021734A KR 20217021734 A KR20217021734 A KR 20217021734A KR 102828472 B1 KR102828472 B1 KR 102828472B1
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- delete delete
- peaks
- cell
- xrpd pattern
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020257021669A KR20250103803A (ko) | 2018-12-13 | 2019-12-12 | 키나아제 억제제의 결정질 형태 및 염 형태 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862779430P | 2018-12-13 | 2018-12-13 | |
| US62/779,430 | 2018-12-13 | ||
| US201962856469P | 2019-06-03 | 2019-06-03 | |
| US62/856,469 | 2019-06-03 | ||
| PCT/US2019/065972 WO2020123800A1 (en) | 2018-12-13 | 2019-12-12 | Crystalline forms and salt forms of a kinase inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020257021669A Division KR20250103803A (ko) | 2018-12-13 | 2019-12-12 | 키나아제 억제제의 결정질 형태 및 염 형태 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20210102381A KR20210102381A (ko) | 2021-08-19 |
| KR102828472B1 true KR102828472B1 (ko) | 2025-07-03 |
Family
ID=69160358
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217021734A Active KR102828472B1 (ko) | 2018-12-13 | 2019-12-12 | 키나아제 억제제의 결정질 형태 및 염 형태 |
| KR1020257021669A Pending KR20250103803A (ko) | 2018-12-13 | 2019-12-12 | 키나아제 억제제의 결정질 형태 및 염 형태 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020257021669A Pending KR20250103803A (ko) | 2018-12-13 | 2019-12-12 | 키나아제 억제제의 결정질 형태 및 염 형태 |
Country Status (33)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117402114A (zh) * | 2018-01-26 | 2024-01-16 | 埃克塞里艾克西斯公司 | 用于治疗激酶依赖性病症的化合物 |
| MX2021014773A (es) * | 2019-06-03 | 2022-01-18 | Exelixis Inc | Formas de sales cristalinas de un inhibidor de cinasas. |
| CN115461328B (zh) * | 2020-04-30 | 2025-11-07 | 埃克塞里艾克西斯公司 | 用于制备激酶抑制剂的方法 |
| IL300151A (en) * | 2020-07-31 | 2023-03-01 | Exelixis Inc | Combinations for cancer treatment |
| JP2023548855A (ja) * | 2020-11-05 | 2023-11-21 | エグゼリクシス， インコーポレイテッド | キナーゼ阻害剤の医薬組成物 |
| CN112650176B (zh) * | 2020-12-22 | 2022-08-30 | 天能化工有限公司 | 一种盐酸解析开停车工序的dcs控制方法 |
| TW202334090A (zh) * | 2021-11-03 | 2023-09-01 | 美商艾克塞里克斯公司 | 用於治療激酶依賴性病症之化合物 |
| US20250368606A1 (en) | 2021-12-22 | 2025-12-04 | Exelixis, Inc. | Crystalline forms and salt forms of a kinase inhibitor |
| CN116751161A (zh) * | 2023-06-28 | 2023-09-15 | 中国人民解放军军事科学院军事医学研究院 | 喹啉类化合物及其制备方法、药物组合物及医药用途 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005030140A2 (en) | 2003-09-26 | 2005-04-07 | Exelixis, Inc. | C-met modulators and methods of use |
| WO2018218233A1 (en) | 2017-05-26 | 2018-11-29 | Exelixis, Inc. | Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use |
| WO2019148044A1 (en) | 2018-01-26 | 2019-08-01 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2604238C (en) | 2005-04-15 | 2015-07-07 | Neogenix Oncology, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
| ES2599458T3 (es) | 2008-10-14 | 2017-02-01 | Sunshine Lake Pharma Co., Ltd. | Compuestos y métodos de uso |
| NZ779754A (en) | 2009-01-16 | 2023-04-28 | Exelixis Inc | Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
| CN102408411B (zh) | 2011-09-19 | 2014-10-22 | 北京康辰药业股份有限公司 | 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
| BR112015007672A2 (pt) | 2012-10-04 | 2017-08-08 | Dana Farber Cancer Inst Inc | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso |
| SMT202100065T1 (it) | 2013-05-02 | 2021-03-15 | Anaptysbio Inc | Anticorpi diretti contro la proteina della morte programmata (pd-1) |
| BR112016018450A2 (pt) | 2014-02-14 | 2018-09-18 | Exelixis Inc | formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, processos de preparo e métodos de uso |
| CN104817497B (zh) | 2015-03-20 | 2017-03-08 | 南京众睿缘生物科技有限公司 | 一种炔代喹啉衍生物及其制备方法和用途 |
| MX2021014773A (es) * | 2019-06-03 | 2022-01-18 | Exelixis Inc | Formas de sales cristalinas de un inhibidor de cinasas. |
-
2019
- 2019-12-12 KR KR1020217021734A patent/KR102828472B1/ko active Active
- 2019-12-12 PL PL19836338.4T patent/PL3894012T3/pl unknown
- 2019-12-12 JP JP2021533537A patent/JP7509779B2/ja active Active
- 2019-12-12 PT PT198363384T patent/PT3894012T/pt unknown
- 2019-12-12 IL IL320433A patent/IL320433A/en unknown
- 2019-12-12 GE GEAP201915695A patent/GEP20247596B/en unknown
- 2019-12-12 DK DK19836338.4T patent/DK3894012T3/da active
- 2019-12-12 ES ES19836338T patent/ES3052838T3/es active Active
- 2019-12-12 WO PCT/US2019/065972 patent/WO2020123800A1/en not_active Ceased
- 2019-12-12 HU HUE19836338A patent/HUE072868T2/hu unknown
- 2019-12-12 MA MA54458A patent/MA54458B1/fr unknown
- 2019-12-12 MD MDE20211022T patent/MD3894012T2/ro unknown
- 2019-12-12 LT LTEPPCT/US2019/065972T patent/LT3894012T/lt unknown
- 2019-12-12 PE PE2021000862A patent/PE20211757A1/es unknown
- 2019-12-12 FI FIEP19836338.4T patent/FI3894012T3/fi active
- 2019-12-12 CR CR20210375A patent/CR20210375A/es unknown
- 2019-12-12 KR KR1020257021669A patent/KR20250103803A/ko active Pending
- 2019-12-12 SI SI201930963T patent/SI3894012T1/sl unknown
- 2019-12-12 EP EP25183289.5A patent/EP4631505A3/en active Pending
- 2019-12-12 AU AU2019395419A patent/AU2019395419B2/en active Active
- 2019-12-12 CA CA3122840A patent/CA3122840A1/en active Pending
- 2019-12-12 RS RS20250909A patent/RS67216B1/sr unknown
- 2019-12-12 MX MX2021006951A patent/MX2021006951A/es unknown
- 2019-12-12 SG SG11202105949RA patent/SG11202105949RA/en unknown
- 2019-12-12 US US17/312,658 patent/US12017995B2/en active Active
- 2019-12-12 BR BR112021011333-9A patent/BR112021011333A2/pt unknown
- 2019-12-12 SM SM20250346T patent/SMT202500346T1/it unknown
- 2019-12-12 IL IL283860A patent/IL283860B2/en unknown
- 2019-12-12 HR HRP20251122TT patent/HRP20251122T1/hr unknown
- 2019-12-12 CN CN201980090041.5A patent/CN113329790A/zh active Pending
- 2019-12-12 EP EP19836338.4A patent/EP3894012B1/en active Active
- 2019-12-13 TW TW108145868A patent/TWI852963B/zh active
-
2021
- 2021-06-04 ZA ZA2021/03844A patent/ZA202103844B/en unknown
- 2021-06-09 PH PH12021551356A patent/PH12021551356A1/en unknown
- 2021-06-10 CO CONC2021/0007613A patent/CO2021007613A2/es unknown
- 2021-06-11 CL CL2021001537A patent/CL2021001537A1/es unknown
-
2023
- 2023-12-27 JP JP2023221085A patent/JP7783870B2/ja active Active
-
2024
- 2024-05-07 US US18/657,052 patent/US20240300897A1/en active Pending
-
2025
- 2025-09-22 AU AU2025234277A patent/AU2025234277A1/en active Pending
- 2025-11-28 JP JP2025208367A patent/JP2026031599A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005030140A2 (en) | 2003-09-26 | 2005-04-07 | Exelixis, Inc. | C-met modulators and methods of use |
| WO2018218233A1 (en) | 2017-05-26 | 2018-11-29 | Exelixis, Inc. | Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use |
| WO2019148044A1 (en) | 2018-01-26 | 2019-08-01 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102828472B1 (ko) | 키나아제 억제제의 결정질 형태 및 염 형태 | |
| KR102826380B1 (ko) | 카이네이스 저해제의 결정질 염 형태 | |
| US20250368606A1 (en) | Crystalline forms and salt forms of a kinase inhibitor | |
| HK40061293B (en) | Crystalline forms and salt forms of a kinase inhibitor | |
| HK40061293A (en) | Crystalline forms and salt forms of a kinase inhibitor | |
| EA048718B1 (ru) | Кристаллические солевые формы ингибитора киназы | |
| HK40067664A (en) | Crystalline salt forms of a kinase inhibitor | |
| BR122025022768A2 (pt) | Formas cristalinas, sais de ácido clorídrico e ácido fosfórico cristalinos, composição farmacêutica e usos relacionados | |
| EA044424B1 (ru) | Кристаллические формы и солевые формы ингибитора киназы | |
| OA20944A (en) | Crystalline salt forms of a kinase inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20210712 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20221209 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20250113 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20250327 |
|
| PG1601 | Publication of registration |